Adverse events were reported in 80.9% of study participants, including 91.7% receiving semaglutide alone, 82.5% receiving nimacimab alone, 78.6% receiving nimacimab plus semaglutide, and 75% receiving placebo
Frontiers in Endocrinology, 16 , 1754430
Following legal challenges, DHHS reversed these reductions entirely, including the restoration of coverage for GLP-1 medications used for weight management effective December 12, 2025, by direct order of the governor
Your weight loss goals should not be limited by finances
Concordantly, both Skeletal Muscle Mass (SMM) and Skeletal Mass Index (SMI) were found to be preserved during therapy, despite no specific exercise recommendations were provided
change in stools